Last reviewed · How we verify

NCT06324123: NEURATIL

Observational Study Aimed at Evaluating the Trend of Neuropathic Pain

Completed Last updated 31 December 2024
What this trial tests

trial testing Peacetil in Neuropathic Pain in 122 participants. Completed in 20 June 2024.

Timeline
9 June 2023
Primary endpoint
20 June 2024
20 June 2024

Quick facts

Lead sponsorIstituto Auxologico Italiano
StatusCompleted
Study typeOBSERVATIONAL
Enrollment122
Start date9 June 2023
Primary completion20 June 2024
Estimated completion20 June 2024
Sites3 locations across Italy

Drugs / interventions tested

Conditions studied

Sponsor

Istituto Auxologico Italiano — full company profile →

Who can join

Adults 18 to 82, any sex, with Neuropathic Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present study aims to evaluate the trend of neuropathic pain in patients treated with Peacetil for a period of two months. Neuropathic pain will me assessed through the Numeric Rating Scale (NRS) questionnaire score.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Neuropathic Pain

Currently open trials in the same condition.

Other Istituto Auxologico Italiano trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06324123.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing